Pill Rimonabant

Obesity, a problem of our society

Obesity is a major health concern; and obesity is more prevalent than ever before in today’s modern society. Our lifestyles these days are just not conducive to healthy weight management, and we all spend too much time sitting behind a desk, and not enough time getting regular exercise. Many of us are so busy that we don’t even have the time to eat right. The toll of this unhealthy lifestyle is excess fat that builds up over the years, and eventually becomes a major health threat. Obesity has been proven to cause increased cancer prevalence’s, higher risks for heart disease, high cholesterol and high blood pressure. The statistics say that if you are obese, you will not live as long. It can be difficult to lose weight. Anyone who has tried to diet knows how difficult and frustrating the process can be. Your body is accustomed to certain caloric intakes, and your body wants to regulate that intake at a steady level. If you try to cut down your caloric consumption, your body will react, and you will feel constant hunger.(pill rimonabant)
Diet pills have been available for some time; but most of these drugs either didn’t work, or they did work, but the side effects and dangers were so severe, that it simply wasn’t worth continuing. Thankfully, that has now changed. The release of Acomplia (pill rimonabant) now provides obese people with a safe and effective medical aid for weight loss.
Clinical studies have proven Acomplia to be the safest and most effective weight loss drug ever developed. Acomplia will help you lose weight, safely.

Anti Obesity Anti Smoking Pill 

A pill that helps you lose weight and quit smoking? That was amazing enough to capture headlines last week. But scientists say the experimental drug might be even more versatile, providing a new tool to help people stop abusing drugs and alcohol, too. It’s called Pill Rimonabant, or Acomplia (search), and last week researchers reported it could help people not only lose weight but keep it off for two years. That burnished the drug’s reputation after two studies in March, which suggested it could fight both obesity and smoking, two of humanity’s biggest killers. The French pharmaceutical firm Sanofi-Aventis plans to seek federal approval for Pill Rimonabant next year. But the drug’s benefits may go beyond just smokers and obese people, researchers say. “I think it’s going to have a big impact on the treatment of addiction,” said Dr. Charles O’Brien, an addiction expert at the University of Pennsylvania and the Philadelphia Veterans Affairs Medical Center. Animal studies suggest Pill Rimonabant can block the effects of marijuana and fight relapse in alcohol and cocaine abuse, he said. Once it is approved for treating obesity or smoking, “we’ll be free to study it in these other areas and I’ll try to get my hands on it as quickly as possible,” O’Brien said. He’s not alone in his enthusiasm.The National Institute on Alcohol Abuse and Alcoholism is interested in seeing whether Pill Rimonabant (search) can help treat heavy drinkers, said Dr. George Kunos of the institute. No human test results for Pill Rimonabant in alcohol abuse have yet been published, he said.But researchers at the National Institute on Drug Abuse reported in 2001 that a single dose of the drug could block the effects of smoked marijuana in people, not just animals. That suggests the drug could be useful in treating marijuana dependence (search), said Marilyn Huestis, principal investigator of the study. The institute is now pursuing follow-up research, said Huestis, acting chief for chemistry and drug metabolism research at NIDA.Pill Rimonabant’s versatility traces back to its effects on the brain’s reward system, circuitry that tells you to keep on doing something. Basically, it appears to help break the connection between an activity like smoking and the rewarding feeling it causes in the brain.The body has its own marijuana-like substances called endocannabinoids, and they activate certain brain cells that in turn can lead to stimulation of the brain’s reward system. Pleasurable things like drinking alcohol are thought to activate a feeling of reward by acting through the endocannabinoid (search) system.”We think that the (endocannabinoid) system is overactivated by chronic smoking, or perhaps even excessive overeating,” said Dr. Robert Anthenelli of the University of Cincinnati College of Medicine and the Cincinnati Veterans Affairs Medical Center. He’s on the advisory board of Sanofi-Aventis.Pill Rimonabant blocks the effect of the natural endocannabinoids by keeping them from latching onto the brain cells they normally stimulate, he said. In smokers, for example, that seems to restore the natural balance of the brain reward circuitry, he said.
Buy Pill Rimonabant

Rimonabant (Acomplia, Zimulti) is an anti-obesity diet pill and has the potential as a smoking cessation drug. It offers solution to improve a variety of cardiometabolic risk factors in obese and overweight people. These risk factors include high LDL cholesterol levels, hypertension and diabetes and other factors being investigated as insulin resistance, low HDL cholesterol, and high triglyceride levels. Rimonabant comes in the form of 20mg pill to be taken daily.

Rimonabant acts by blocking the CB1 receptors are found in the brain and in the peripheral organs and are part of the endocannabinoid system which is believed to play an important role in regulating body weight and controlling energy balance. Rimonabant blocks CB1 receptors and thus decreases the hyperactivity of the endocannabinoids system resulting in less intake of food which in turn leads to weight loss.(buy rimonabant pill)

Based on the data available from various clinical trials, Rimonabant (Acomplia, Zimulti,buy rimonabant pills) is an extremely safe medication with minor side effects such as nausea, mood swings, anxiety and dizziness.Rimonabant is recommended to be taken along with regular exercise and a diet regime for optimum results. Patients with a Body Mass Index (BMI) greater than or equal to 30kg/m2 can benefit from taking a daily pill of Rimonabant of 20mg along with proper exercise and diet.Various trials conducted have shown remarkable results making Rimonabant (Acomplia, Zimulti) one of the most sought after anti-obesity medications worldwide.

Rimonabant is also known as wonder drug as it treats obesity and smoking cessation simultaneously.Rimonabant (brand name Acomplia,buy rimonabant pill) is an anorectic anti-obesity drug. It is a CB1 cannabinoid receptor antagonist. Its main avenue of effect is reduction in appetite. Rimonabant is currently being sold in the United Kingdom by Sanofi-Aventis and in Denmark by Sanofi-Synthelabo under the trade name Acomplia. It is believed, although not confirmed, that if the drug is approved in the United States, it will be sold under the trade name Zimulti.(buy rimonabant pill)

Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. In Europe, it is indicated for use in conjunction with diet and exercise for patients with a body mass index greater than 30 kg/m2, or patients wih a BMI greater than 27 kg/m2 with associated risk factors, such as type 2 diabetes or dyslipidaemia. In the UK it has been available since the end of July, 2006.Rimonabant may also be found to be effective in assisting some smokers to quit smoking. Sanofi-Aventis is currently conducting studies to determine the possible value of rimonabant in smoking-cessation therapy.
Buy Rimonabant Pill 

One-stop shopping fans take note: a new pill that claims to help people stop smoking and lose weight at the same time is in its final stages of testing. It could be on the market by 2006. The new drug is called Rimonabant Acomplia, and its being developed by the French firm Sanofi-Synthelabo.

Summary:

A single pill has been found to stop both food and cigarette cravings enough to help people quit smoking and lose weight, and could also help curb other unhealthy urges.
Named Rimonabant Acomplia the drug in one study helped people who were overweight drop an average of 20 pounds and in another doubled the chances that smokers would quit.
Rimonabant (which will be brought to market as Rimonabant Acomplia) works by blocking the CB1 receptor, one of two receptors found in a newly described physiological system called the Endocannabinoid System (EC System), believed to play a critical role in the regulation of food intake and energy expenditure.
Researchers wondered whether a drug that halted this action might curb appetite, and in 2001, the first animal study was conducted at the National Institute of Alcohol Abuse and Alcoholism in Bethesda, Md.
When the normal mice were given rimonabant, which blocked their CB1 receptors, the mice reduced their food intake.In 2002, Sanofi-Synthelabo began human testing.
Rimonabant Acomplia works by selectively targeting and blocking the CB1 receptors, helping normalize the over-activation of the EC system and making hunger or cigarette cravings more manageable.
This blocking of signals that control cravings appears to result in weight loss, improvement of cardiovascular/ metabolic risk factors in overweight/obese patients and appears to reduce tobacco dependence without post cessation weight gain in people who smoke.
Meridia (Reductil in Europe) was originally a drug meant to treat depressions and can have severe side-effects as well, like high blood pressure, sleeping problems (Insomnia), constipation and dry-mouth syndrome.
This causes a lot of strain on many of the body systems and phentermine should therefore not be used for longer periods and only in obesity cases and not for treating common overweight.

Here’s another article that promotes the hype and mythology of Acomplia, an upcoming weight loss drug that still remains entirely unproven. Amazingly, even the fitness industry seems concerned about Acomplia now. But it’s ridiculous: no pill can make a person look fit. Nor can it actually improve a person’s cardiovascular health. There’s no replacement for physical exercise, but of course, Americans will probably buy into Acomplia anyway, because even the promise of weight loss without effort is good enough to cause an explosion in sales.
A much better approach to losing weight with the help of drugs is probably the upcoming PYY nasal spray product from Nastech / Merck. This uses a natural hormone (PYY) that you inhale to make you feel full more quickly.

Summary:

One of the big health stories of 2004 was development of Acomplia, also known as Rimonabant, a diet drug which shows real promise for sustained weight loss.
In early clinical trials, Acomplia is looking promising.
But with only 3,000+ people tested so far, it has a way to go before being approved by the FDA.
With the raging obesity problem, more and more people are seeking ways to lose weight without the pain and drudgery of dieting or working out.
The fitness industry frowns upon the notion of popping a pill to lose weight after all the battle cry is “The pain is the gain”.
Yet the idea of a diet pill is seductive.
It’s something that doesn’t require any exertion whatsoever, and that makes it a perfect fit for many Americans, who seem increasingly unwilling to actually take any action in order to achieve lasting results.
What they want is a magic weight loss pill.
And so far, Acomplia looks like the closest solution.
The drug’s manufacturer, Sanofi-Aventis, an international pharmaceutical, headquartered in Paris, plans to apply for FDA approval in 2005.
A decision by the agency will then take up to 10 months.
Diet pills have been around for decades offering different attempts at suppressing appetite or speeding up the metabolism.
But Acomplia offers a new technology known as a cannabinoid type I (CB1) blocker, it’s the first of an entirely new class of drugs, which works by blocking a pleasure center in the brain.
From the standpoint of researchers, the drug is clearly a breakthrough.
Will the entire fitness industry be challenged one day by the discovery of a magic diet pill?